MoHAP to allow Pfizer-BioNTech vaccine for children aged 5-11

MoHAP to allow Pfizer-BioNTech vaccine for children aged 5-11

MoHAP has authorised the emergency use of Pfizer-BioNtech COVID-19 vaccine for those in the age group of 5-11 years, based on results of clinical studies and rigorous assessment followed by emergency use authorisation and local assessment in compliance with approved regulations and after approval by the US Food and Drug Administration (FDA).

The approval of the vaccine represents a critical stage that will strengthen prevention among this age group. The results of clinical studies indicated that the vaccine is safe and has given a strong immune response to children between the age of 5 and 11 years.

News Source: Emirates News Agency

- Advertisement -
Dark Light